Best Neurology Companies in London, United Kingdom
The 50 best Neurology companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Markit.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Markit Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders | $750M | 158 mo ago | 1,030 | — | Public | — | — |
| 2 | COMPASS Pathways Developer of therapies for treating mental disorders | $109M | 35 mo ago | 42 | Lars Wilde Co-Founder | Public | 23 patents Patents concentrated in chemistry & materials | — |
| 3 | Proximagen Small molecules for neurodegenerative disorders, including Parkinson’s and Alzheimers. | $96M | 178 mo ago | 28 | Peter Jenner Founder | Acquired | 349 patents Small-molecule SSAO and CXCR4 receptor inhibitors for therapeutic applications | — |
| 4 | Alchemab Developer of antibody therapeutics for treating oncology and neurodegenerative conditions 45Funding top 28%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 28% Talenttop 28% Moattop 31% Growthtop 35% Globalbottom 37% Marketbottom 34% Techbottom 33% Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $83M | 10 mo ago | 8 | Jane Osbourn Co-Founder & CEO | Series A | — | — |
| 5 | AviadoBio Developer of gene therapies for neurodegenerative disorders | $80M | 56 mo ago | 38 38 → 70 (+84%) | Do Lee Co-Founder | Series A | 3 patents Antisense nucleic‑acid therapies targeting SOD1 for ALS and CNS drug delivery platforms. | 1 launch · 1 partnership |
| 6 | AstronauTx Developer of therapeutics for neurodegenerative disorders | $61M | 34 mo ago | 5 | Ruth Mckernan Co-Founder | Series A | — | 1 award |
| 7 | CoMind Provider of a non-invasive brain-computer interface solution for various industries 55Growth top 11%News top 24%Funding top 29%Moat top 42% All 9 signals ▾Growthtop 11% Newstop 24% Fundingtop 29% Moattop 42% Partnerstop 45% Talentbottom 49% Marketbottom 38% Globalbottom 37% Techbottom 36% Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $60M | 9 mo ago | 36 36 → 81 (+125%) | James Dacombe Co-Founder & CEO | Series A | — | — |
| 8 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 66 mo ago | 9 | Vicente Gonzalez Co-Founder | Deadpooled | — | — |
| 9 | Small Pharma Developer of psychedelic-based therapeutics for mental health conditions | $49M | 65 mo ago | 8 | — | Acquired | 148 patents Deuterated psychedelic compounds and specialized delivery formulations for psychiatric therapies | — |
| 10 | Kesmalea Developer of protein homeostasis modulators for therapeutic applications | $30M | 23 mo ago | 5 | Harry Finch Founder Director | Series B | — | — |
| 11 | Endlyz Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases 24Funding top 32%Tech bottom 49%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 32% Techbottom 49% Talentbottom 49% Globalbottom 48% Marketbottom 25% Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel rank vs industry peers · Fliar Intelligence Index 24/100 | $17M | 4 mo ago | — | Joanna Wolak Co-Founder & CEO | Series B | — | — |
| 12 | Calchan Developing Calcium channel blocker to treat neuropathic pain and apoptosis signal-regulating kinase 1… | $13M | 164 mo ago | 1 | Brenda Reynolds CEO | Deadpooled | 17 patents Small-molecule ASK1 kinase inhibitors for inflammation and neurodegeneration therapies | — |
| 13 | OKYO Pharma Developer of therapeutics for the treatment of dry eye disease and chronic pain management | $10M | 12 mo ago | 6 | Gary Jacob Chief Executive Officer | Public | — | 1 expansion |
| 14 | Neurofenix Manufacturer of medical devices for neurorehabilitation | $7M | 47 mo ago | 6 | — | Series A | 6 patents Rehabilitation devices for motor training and therapy | — |
| 15 | Istesso Immunometabolism based drugs for autoimmune diseases | $7M | 91 mo ago | 5 | Lisa Patel Co-Founder & CEO | Series A | 21 patents Combination therapies targeting NF‑κB, TNF, JAK/IL‑6 pathways for inflammatory disease treatment | — |
| 16 | BioCorteX Developer of human-microbiome platform for drug development | $5M | 40 mo ago | 13 | Nik Sharma Co-Founder & CEO | Seed | — | 1 award |
| 17 | LivaNova Provider of cardiac and neurological therapeutic devices | $5M | 67 mo ago | 68 | Vladimir Makatsaria CEO | Public | — | — |
| 18 | GyroGear Provider of smart gloves for people suffering from Parkinson's disease | $4M | 59 mo ago | 10 10 → 15 (+50%) | — | Seed | 71 patents Wearable medical devices for tremor detection, stabilization, and management in patients. | 2 launchs |
| 19 | Canbex Therapeutics Antispastic small molecule drugs for multiple sclerosis | $3M | 160 mo ago | 1 | — | Acqui-Hired | 27 patents Novel benzamide compounds activating BKCa channels for muscle spasticity and pain relief | — |
| 20 | Solvonis Therapeutics Developer of novel therapeutics for addiction and mental health disorders | $3M | 9 mo ago | — | Anthony Tennyson Co-Founder & Chief Executive Officer | Public | — | — |
| 21 | Aptorum Group Developer of small molecular therapeutics for multiple disorders | $3M | 44 mo ago | 26 | Ian Huen Founder & CEO | Public | — | — |
| 22 | VacV Developer of immuno-therapeutics for cancer treatment | $3M | 44 mo ago | 6 | Peng Liu Co-Founder | Seed | — | — |
| 23 | SERG Technologies Provider of neurodegenerative monitoring devices for patients | $2M | 48 mo ago | 5 | Sam Wilson Co-Founder | Seed | — | — |
| 24 | MYndspan Platform offering detailed reports on cognitive function and brain connectivity | $2M | 15 mo ago | 5 | Caitlin Baltzer Co-Founder | Seed | — | — |
| 25 | Mursla Provider of diagnostic device for cancer detection | $547K | 71 mo ago | 9 | Victor Serdio Co-Founder | Seed | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | 1 award |
| 26 | Eleusis Developer of immunomodulatory and neuroprotective medicines | $495K | 53 mo ago | 1 | Charles Nichols Co-Founder | Acquired | — | — |
| 27 | Cortirio Developer of smart devices for neurological disorders management | — | 69 mo ago | 4 | Paul Macey Co-Founder | Seed | 19 patents Near-infrared medical imaging and photometric measurement technologies for diagnostic applications. | — |
| 28 | Orexia Provider of drugs for treating neurological disease | — | 78 mo ago | 2 | — | Seed | — | — |
Top 12 Neurology companies in London
#1
Series B · London, England · founded 2021$17.3Mraised▾
Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases. The company focuses on developing disease-modifying therapies to restore endo-lysosomal function and reduce neurodegeneration. Their pipeline includes small molecule modulators targeting ATP13A2 and ATP10B lysosomal transporters, both critical for maintaining neuronal health. Initial clinical indications target genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other neurodegenerative disorders. The approach aims to address the underlying causes of these diseases rather than just managing symptoms.
- Mar 2026Series B$17.3M
#2
Series A · London, England · founded 2019 · 8 employees$82.7Mraised▾
Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.
- Sep 2025Series A$32M
- Dec 2022Grant (prize money)$2.1M
- 2021Grant (prize money)—
- Apr 2021Series A$82.7M
#3
Series A · London, England · founded 2017 · 36 employees$60Mraised▾
Provider of a non-invasive brain-computer interface solution for various industries. It enables users to develop, design, measure, study, record, process, analyze, manage, and control brain data for decision-making. Its offering includes application development, research, neuroimaging, and stimulation technologies. It caters to the health and manufacturing industries.
- Oct 2025Series A$60M
- 2023Seed—
#4
Public · London, England · founded 2018 · 6 employees$10.4Mraised▾
Developer of therapeutics for the treatment of dry eye disease and chronic pain management. The company's lead candidate is OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. It is also developing a non-opioid analgesic BAM8 utilizing oral and nasal formulations for the management of chronic pain.
- Jul 2025Grant (prize money)$1.9M
- Jan 2025Post IPO$1.4M
- Sep 2020Post IPO$659.5K
- Aug 2020Post IPO$1.9M
#5
Public · London, England · founded 2017$3Mraised▾
Developer of novel therapeutics for addiction and mental health disorders. This company focuses on creating new medicines to address the limitations of existing treatments for these conditions. The initial therapeutic focus is on post-traumatic stress disorder (PTSD). The goal is to provide effective solutions that improve patient outcomes and reduce the significant societal and economic burdens associated with these disorders.
- Oct 2025Post IPO$1.7M
- Jul 2025Post IPO$1.4M
#6
Series B · London, England · founded 2020 · 5 employees$30.5Mraised▾
Developer of protein homeostasis modulators for therapeutic applications. The company is focused on discovering novel protein degraders for maintaining the equilibrium of proteins in the human body. The company's intricate system is used for continuously synthesising and regulating proteins.
- Sep 2024Series B$13.1M
- Sep 2023Series B$12.7M
- Sep 2022Series A$5.8M
- 2022Series A$30.5M
#7
Seed · London, England · founded 2020 · 5 employees$1.8Mraised▾
Platform offering detailed reports on cognitive function and brain connectivity. It use non invasive brain scan technology to improve brain health and extend the healthy lifespan of the mind. The services are designed to assess cognitive health, identify conditions such as concussions or PTSD, and support preventive care for neurological conditions.
- Apr 2025Seed—
- Dec 2024Seed$464.3K
- Jan 2023Seed$995.4K
- Sep 2022Seed$1M
#8
Public · London, England · founded 2016 · 42 employees$108.6Mraised▾
Developer of therapies for treating mental disorders. The company is developing psilocybin therapy (a psychoactive medicine) for the treatment of resistant depression which acts as a partial agonist for several serotonin receptors.
- Aug 2023Post IPO$285M
- Apr 2020Series B$80M
- Oct 2018Series A$28.6M
#9
Series A · London, England · founded 2019 · 5 employees$61Mraised▾
Developer of therapeutics for neurodegenerative disorders. The company offers a proprietray platform “AstronauTx is a novel approach to restore the homeostatic function and treats neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
- Oct 2023Series A$61M
- Sep 2023Grant (prize money)—
- 2019Seed—
#10
Public · London, England · founded 2003 · 1030 employees$750Mraised▾
Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders. It focuses on discovering treatments by targeting dynamic synaptic plasticity. The company’s negative allosteric modulator program has been licensed for development of a fast-acting treatment. In-house discovery efforts focus on agents for addressing cognitive impairment through positive allosteric modulation. Short Description: Online marketplace for buying and selling second-hand clothes from influencers Long Description: Online marketplace for buying and selling second-hand clothes from influencers. The marketplace allows influencers to collaborate with brands and market and sell products. It also allows brands to sell their products directly without using an influencer. Short Description: Hub assisting businesses with development and fast-tracking content to markets Long Description: Hub assisting businesses with development and fast-tracking content to markets. It helps in business development to fast-track content, products, and services to global markets. Short Description: Platform for development and networking in logistics and mobility sectors Long Description: Platform for develo
#11
Series A · London, England · founded 2019 · 38 employees$80Mraised▾
Developer of gene therapies for neurodegenerative disorders. The company is developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company's product candidate include AVB-PGRN an adeno-associated virus (AAV) gene therapy for patients with Frontotemporal Dementia (FTD) with mutations in the Progranulin (GRN) gene.
- Dec 2021Series A$80M
#12
Acquired · London, England · founded 2015 · 8 employees$49.2Mraised▾
Developer of psychedelic-based therapeutics for mental health conditions. The company is focusing on the development of tryptamine-based psychedelic drug candidates by using proprietary deuterium enriching technology. The drug pipeline includes SPL026, SPL028, SPL029, and SPL801 an injectable and oral DMT therapy for Depressive Disorder.
- Mar 2021Series A$46M
- Jul 2019Seed$911.7K
- Dec 2018Seed$197.2K
- Apr 2017Grant (prize money)$173.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neurotech in London is moving
A read on the academic research around Neurotech in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 802 papers.
- University College London388
- Imperial College London194
- King\'s College London136
- St George\'s, University of London45
- Queen Mary University of London34
- Optogenetics1→5
- Stimulation5→9
- Neurostimulation1→5
- Deep brain stimulation19→22
- Disease1→4
- Neuromodulation5→13
- Electroencephalography1→8
- Brain stimulation4→11
- Epilepsy2→9
- Essential tremor6→11
- Neuromodulation7→15
- Neurostimulation3→10
- Transcranial direct-current stimulation5→9
- Brain stimulation5→9
- Vagus nerve stimulation2→6
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.